"Neprilysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
Descriptor ID |
D015260
|
MeSH Number(s) |
D08.811.277.656.300.480.600 D08.811.277.656.675.374.600 D23.050.285.550 D23.101.140.500
|
Concept/Terms |
Neprilysin- Neprilysin
- CALLA Antigen
- Enkephalinase
- Enkephalinase-24.11
- Enkephalinase 24.11
- Kidney-Brush-Border Neutral Proteinase
- Kidney Brush Border Neutral Proteinase
- Neutral Proteinase, Kidney-Brush-Border
- Membrane Metallo-Endopeptidase
- Membrane Metallo Endopeptidase
- Metallo-Endopeptidase, Membrane
- Neutral Endopeptidase
- Endopeptidase, Neutral
- Neutral Endopeptidase 24.11
- Endopeptidase 24.11, Neutral
- Thermolysin-Like Metalloendopeptidase
- Metalloendopeptidase, Thermolysin-Like
- Thermolysin Like Metalloendopeptidase
- YGG-Forming Enzyme
- Enzyme, YGG-Forming
- YGG Forming Enzyme
- Common Acute Lymphoblastic Leukemia Antigens
- Antigens, Leukemia, Common Acute Lymphoblastic
- Atriopeptidase
- CD10 Antigen
- Antigen, CD10
- Antigens, CD10
- CD10 Antigens
- Endopeptidase-24.11
- Endopeptidase 24.11
- Enkephalin Dipeptidyl Carboxypeptidase
- Carboxypeptidase, Enkephalin Dipeptidyl
- Dipeptidyl Carboxypeptidase, Enkephalin
|
Below are MeSH descriptors whose meaning is more general than "Neprilysin".
Below are MeSH descriptors whose meaning is more specific than "Neprilysin".
This graph shows the total number of publications written about "Neprilysin" by people in this website by year, and whether "Neprilysin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2007 | 1 | 1 | 2 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 2 | 1 | 3 |
2011 | 0 | 1 | 1 |
2012 | 1 | 1 | 2 |
2013 | 1 | 2 | 3 |
2014 | 3 | 1 | 4 |
2015 | 1 | 2 | 3 |
2016 | 2 | 3 | 5 |
2017 | 0 | 2 | 2 |
2018 | 5 | 1 | 6 |
2019 | 1 | 1 | 2 |
2020 | 2 | 1 | 3 |
2021 | 2 | 3 | 5 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neprilysin" by people in Profiles.
-
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 09; 24(9):1591-1598.
-
Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats. Ren Fail. 2021 Dec; 43(1):315-324.
-
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021 09 21; 42(36):3741-3752.
-
Incidence and Outcomes of Pneumonia in Patients With Heart?Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
-
Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Circ Heart Fail. 2021 04; 14(4):e007901.
-
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail. 2021 04; 8(2):1706-1710.
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
-
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol. 2020 08 04; 76(5):503-514.
-
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. Circ Heart Fail. 2020 02; 13(2):e006696.
-
Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 12 10; 74(23):2858-2873.